sacituzumab govitecan-hziy Jun 5, 2022 TROPiCS-02 Trial Sees Progression-Free Survival Edge for Trodelvy-Treated Advanced Breast Cancers Apr 29, 2022 Gilead Sciences More Than Doubles Q1 Trodelvy Sales Mar 7, 2022 Gilead to Pursue Expanded Breast Cancer Indication for Trodelvy Following Phase III Data Feb 2, 2022 Gilead Sciences Q4 Cell Therapy Sales Increase 47 Percent Dec 8, 2021 AstraZeneca, Daiichi Sankyo Unveil First Datopotamab Deruxtecan TNBC Data at SABCS Nov 23, 2021 European Commission Approves Gilead's Trodelvy for Metastatic TNBC Oct 29, 2021 Gilead Sciences Q3 CAR T-Cell Therapy Sales Increase 51 Percent Oct 15, 2021 CHMP Recommends Gilead's Trodelvy for Pretreated TNBC Jul 30, 2021 Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent Dec 11, 2020 Gilead's Trodelvy Benefits TNBC Patients Regardless of Trop-2 Expression, BRCA1/2 Status Premium Nov 4, 2020 Immunomedics' Trodelvy Enters Phase II Triple-Negative Breast Cancer Trial in China Sep 20, 2020 ESMO Studies Present New Treatment Options for Advanced Triple-Negative Breast Cancer Premium Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
